NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 82 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,410,000 | -4.0% | 48,500 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,469,000 | +71.6% | 48,500 | -9.8% | 0.00% | 0.0% |
Q3 2020 | $856,000 | -18.2% | 53,774 | +1.5% | 0.00% | 0.0% |
Q2 2020 | $1,046,000 | +148.5% | 52,988 | +55.2% | 0.00% | 0.0% |
Q1 2020 | $421,000 | – | 34,150 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
BVF INC/IL | 955,000 | $18,833,000 | 0.71% |